---
title: "Antibody-Drug Conjugates In Gynaecological Cancers: Current Landscape"
id: "nature-reviews-clinical-oncology-5-antibody-drug-conjugates-in-gynaecological-cancers-opportunities-and-challenges"
canonical_url: "https://medichelpline.com/clinical-feed/nature-reviews-clinical-oncology-5-antibody-drug-conjugates-in-gynaecological-cancers-opportunities-and-challenges"
content_type: "clinical_feed_article"
specialty: "Oncology"
source_name: "Nature Reviews Clinical Oncology"
source_url: "https://www.nature.com/articles/s41571-026-01164-9"
published_at: "2026-06-17T12:00:00.000Z"
evidence_level: "Journal Feed"
license: "CC-BY-NC-4.0 / Informational Use"
---
# Antibody-Drug Conjugates In Gynaecological Cancers: Current Landscape
## Provenance & Clinical Metadata
- **Canonical URL:** https://medichelpline.com/clinical-feed/nature-reviews-clinical-oncology-5-antibody-drug-conjugates-in-gynaecological-cancers-opportunities-and-challenges
- **Specialty:** [Oncology](https://medichelpline.com/clinical-feed/oncology.md)
- **Primary Source:** Nature Reviews Clinical Oncology
- **Source URL:** [Original Journal Publication](https://www.nature.com/articles/s41571-026-01164-9)
- **Published At:** 2026-06-17T12:00:00.000Z
- **Evidence Rating:** Journal Feed
## Executive GIST (TL;DR)
Antibody–drug conjugates (ADCs) have transformed the cancer therapeutic landscape over the past two decades, profoundly shaping treatment outcomes across a wide array of indications. Three ADCs are currently approved for previously treated gynaecological cancers: mirvetuximab soravtansine for folate receptor-α-positive ovarian cancer, trastuzumab deruxtecan for solid tumours expressing HER2 (defined as a staining intensity on immunohistochemistry of 3+) and tisotumab vedotin for cervical cancer (independent of tissue factor expression). Current research priorities include identifying novel targets, better understanding mechanisms of resistance and sequencing strategies, and optimal management of the toxicities of ADCs. Moreover, rational combinations could reinforce and extend the clinical potential of these agents, as has already been demonstrated with the addition of ADCs to immune checkpoint inhibitors in an effort to amplify antitumour immunity and prolong the durability of clinical responses. In this Review, we provide an overview of the current landscape of ADCs in gynaecological malignancies, highlighting key advances and future opportunities.
## Clinical Analysis & Structured Key Points
Nature Reviews Clinical Oncology published a clinical update in Oncology on 17 Jun 2026. The item focuses on Antibody–drug conjugates in gynaecological cancers: opportunities and challenges. Review the original article for the full source wording and details.
## Related Clinical Research

- [Antibody-Drug Conjugates for Advanced Esophageal Cancer: Targets, Evidence, and Clinical Integrati](https://medichelpline.com/clinical-feed/pubmed-42700288.md) (DOI: 10.1007/s11864-026-01411-2)
- [Stepwise Molecular Profiling Reveals Co-occurring EGFR L858R and HER2 Amplification in NSCLC](https://medichelpline.com/clinical-feed/pubmed-42681853.md) (DOI: 10.12659/AJCR.953829)
- [VISTA: Virtual spatial transcriptomics from H&E for prognostic and therapy response prediction in](https://medichelpline.com/clinical-feed/biorxiv-21-virtual-spatial-transcriptomics-from-histopathology-enables-prognostic-and.md)
- [Next-generation Antibody–Drug Conjugates: Strategies to Improve Efficacy and Clinical Development](https://medichelpline.com/clinical-feed/nature-0-the-next-generation-of-antibody-drug-conjugates.md)
- [Clinical toxicity of ADCs and ICI–ADC combinations: mechanisms, organ patterns and management](https://medichelpline.com/clinical-feed/nature-reviews-clinical-oncology-0-clinical-toxicity-of-adcs-and-ici-adc-combinations-mechanisms-patterns-and.md)

## Navigation
- [← Back to Oncology Feed](https://medichelpline.com/clinical-feed/oncology.md)
- [← All Clinical Specialties](https://medichelpline.com/clinical-feed.md)
## Medical & Regulatory Disclaimer

> [!CAUTION]
> MedicHelpline content is structured for research, educational, and professional discovery purposes. It does not constitute individual medical advice, clinical diagnosis, or treatment recommendations.
> Always verify dosing, contraindications, and regulatory alerts against official product labeling and primary regulatory sources before clinical decision-making.